Article

Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease

Department of Neurology, V127, University of California, San Diego, 3350 La Jolla Village Drive, San Diego, CA 92161, USA.
Journal of the International Neuropsychological Society (Impact Factor: 3.01). 08/2005; 11(4):446-53. DOI: 10.1017/S1355617705050502
Source: PubMed

ABSTRACT Patients with Alzheimer's Disease (AD) who have reached a stage of moderate to severe dementia are capable of completing a restricted range of cognitive tests and performing a limited range of activities of daily living (ADL). As part of an initiative to develop instruments to evaluate AD, we analyzed data describing the performance of a large number of ADL and scores on cognitive and global assessment measures in a cohort of patients with AD with moderate to severe cognitive impairment, defined as a Mini-Mental State Examination score ranging from 0-15 (out of 30). From the large pool of ADL, 19 met criteria of applicability, reliability, good scaling, concordant validity, and sensitivity to detect change in performance over 6-12 months. A total score derived from these 19 ADL ratings, comprising a scale termed the Alzheimer Disease Cooperative Study ADL-sev, correlated strongly with measures of cognition and of global dementia severity. Patients with moderate to severe AD showed a decline on the ADL-sev and cognitive measures over 6 and 12 months, consistent with the progression of AD. Detailed evaluation of ADL may provide a useful index to evaluate patients with moderate to severe AD and may complement cognitive assessment, especially for characterizing change in interventional or therapeutic studies.

0 Bookmarks
 · 
87 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Impairment in language abilities occurs in a number of neurological conditions, including Alzheimer's disease (AD) and other dementias, primary progressive aphasia, multiple sclerosis and stroke. Currently, no pharmacotherapy is approved for aphasia of any aetiology. Memantine, an antagonist of N-methyl-D-aspartate glutamate receptors that is approved for the treatment of moderate-to-severe AD, has shown promising results on several measures of language and communication in clinical trials.Aims: This review summarises the knowledge gathered from prospective studies and post hoc analyses involving patients with AD and other neurological conditions in whom the effects of memantine treatment on language or communication have been examined.Main Contribution: PubMed searches yielded a total of four prospective studies and three post hoc analyses that assessed the effects of memantine on language and communication in AD (one additional post hoc analysis was published as a conference proceeding only), together with seven prospective studies in other conditions (Parkinson's disease, frontotemporal lobe degeneration, chronic post-stroke aphasia, primary progressive aphasia, multiple sclerosis, risk of dementia). Available data suggest that memantine provides modest language and communication benefits in patients with moderate-to-severe AD; potential benefits in Parkinson's disease and post-stroke aphasia were also observed.Conclusions: Memantine may provide clinical benefits in language and communication in AD and other neurological conditions. Since communication problems create a significant burden for patients and their caregivers, larger prospective trials, conducted to provide more precise estimates of benefits in that domain, are merited.
    Aphasiology 12/2013; 28(2):236-257. DOI:10.1080/02687038.2013.838617 · 1.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION. People with progressive dementia evolve into a state where traditional neuropsychological tests are not effective. Severe Impairment Battery (SIB) and short form (SIB-s) were developed for evaluating the cognitive status in patients with severe dementia. AIM. To evaluate the psychometric attributes of the SIB-s in patients with severe dementia. PATIENTS AND METHODS. 127 institutionalized patients (female: 86.6%; mean age: 82.6 ± 7.5 years-old) with dementia were assessed with the SIB-s, the Global Deterioration Scale (GDS), Mini-Mental State Examination (MMSE), Severe Mini-Mental State Examination (sMMSE), Barthel Index and FAST. RESULTS. SIB-s acceptability, reliability, validity and precision were analyzed. The mean total score for scale was 19.1 ± 15.34 (range: 0-48). Floor effect was 18.1%, only marginally higher than the desirable 15%. Factor analysis identified a single factor explaining 68% of the total variance of the scale. Cronbach's alpha coefficient was 0.96 and the item-total corrected correlation ranged from 0.27 to 0.83. The item homogeneity value was 0.43. Test-retest and inter-rater reliability for the total score was satisfactory (ICC: 0.96 and 0.95, respectively). The SIB-s showed moderate correlation with functional dependency scales (Barthel Index: 0.48, FAST: -0.74). Standard error of measurement was 3.07 for the total score. CONCLUSIONS. The SIB-s is a reliable and valid instrument for evaluating patients with severe dementia in the Spanish population of relatively brief instruments.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HAPEM SHEDS Report for APM 70 (2010): Provide program offices and the exposure science community with human exposure activity pattern and exposure factor data for older adults Source: Dr. Janet Burke. The figures display exposure estimates for different scenarios using the HAPEM (Hazardous Air Pollution Exposure Model) and SHEDS (Stochastic Human Exposure and Dose Simulation) model.